---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010755"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:18:19.286079+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptevo reports 2022 net income of $8.0M on $37.2M gain; cash down to $22.6M

## Summary
- Net income of $8.0M ($1.57 diluted EPS) vs net loss of $28.5M in 2021; includes $37.2M gain on extinguishment of royalty liability.
- Royalty revenue fell to $3.1M from $12.3M due to amendment of royalty purchase agreement with HCR.
- Cash and equivalents $22.6M at Dec 31, 2022, down from $45.0M a year earlier.
- APVO436 Phase 1b data showed activity in AML; Phase 2 planned for 2H23. ALG.APV-527 Phase 1 first patient dosed Feb 2023.
- Preclinical candidate APV0711 (anti-PD-L1/anti-CD40) filed provisional patent; preclinical studies initiated Q1 2023.

## SEC filing metadata
- accession: 0000950170-23-010755
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/0000950170-23-010755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/apvo-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010755
- JSON: https://secwatch.observer/filing/0000950170-23-010755.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010755.txt

## Key facts
- Earnings Releases
  Aptevo Therapeutics Inc. reported year ended December 31, 2022 results: revenue $22.6 million.
  - Period: year ended December 31, 2022
  - Revenue: $22.6 million
  - Result: reported results
  source text: preliminary results from the study later this year.” 3 2022 Summary Financial Results Cash Position: Aptevo had cash and cash equivalents as of December 31, 2022 totaling $22.6 million. Royalty Revenue: Royalty revenue for the period covered by this report reflects revenue recorded only in the first quarter of 2022 due to our Amendment to Royalty Purchase
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/0000950170-23-010755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.